Company news
Liaoning Chengda Biotechnology Co. Ltd. news in 2026
Liaoning Chengda Biotechnology Co. Ltd.'s news releases, calls and decks from 2026, newest first.
(688739)"LIAONING CHENGDA BIOTECHNOLOGY CO., LTD."Announcement on Shareholdings of Top 10 Shareholders and Top 10 Shareholders Holding Unrestricted Shares Concerning Share Repurchase
November 16, 2026
(688739)"LIAONING CHENGDA BIOTECHNOLOGY CO., LTD."Notice on Convening the 3rd Extraordinary General Meeting in 2026
November 10, 2026
(688739)"LIAONING CHENGDA BIOTECHNOLOGY CO., LTD."Announcement on Share Repurchase Plan through Call Auction
November 10, 2026
(688739)"LIAONING CHENGDA BIOTECHNOLOGY CO., LTD."Announcement on Resolutions of the 33rd Meeting of the 5th Board of Directors
November 10, 2026
(688739)"LIAONING CHENGDA BIOTECHNOLOGY CO., LTD."Announcement on Adjustment of Certain Sub-projects of Raised Funds Investment Projects, Termination of Certain Raised Funds Investment Projects, and Continued Deposit of Surplus Raised Funds in Special Account for Raised Funds
November 10, 2026
(688739)"LIAONING CHENGDA BIOTECHNOLOGY CO., LTD."Report for Q3 2026
October 29, 2026
(688739)"LIAONING CHENGDA BIOTECHNOLOGY CO., LTD."Announcement on Subscription for Private Fund Units and Related Party Transaction
October 29, 2026
(688739)"LIAONING CHENGDA BIOTECHNOLOGY CO., LTD."Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
October 13, 2026
(688739)"LIAONING CHENGDA BIOTECHNOLOGY CO., LTD."Announcement on Cancellation of Certain Repurchased Shares, Reduction of Registered Capital and Notice to Creditors
October 13, 2026
Announcement on Change of Registered Capital and Amendments to the Articles of Association
September 24, 2026
Announcement on Expiration of Shareholding Reduction Plan of Senior Executive and Results of Shareholding Reduction
September 21, 2026
Announcement on Convening the 2026 Semi-annual Performance Briefing
September 14, 2026
Special Report on the Deposit and Actual Use of Raised Funds for the First Half of 2026
August 24, 2026
Announcement on the Results of the Special Governance Review by the Audit Committee of the Board of Directors
August 20, 2026
Announcement on the Initiation of Phase I Clinical Trial for Influenza Vaccine (Split Virion, High-Dose)
July 17, 2026
Announcement on Reply to Letter of Supervision and Inquiry on Information Disclosure of 2025 Annual Report
July 10, 2026
Announcement on the Influenza Virus Split Vaccine Obtaining Drug Registration Certificate and Passing GMP Compliance Inspection
July 2, 2026
Announcement on Obtaining Drug Registration Certificate for Quadrivalent Influenza Vaccine (Split Virion) and Passing GMP Compliance Inspection for Drugs
June 16, 2026
Announcement on Implementation Result of Shares Repurchase and Share Changes
June 11, 2026
Announcement on Progress in Joint Investment with the Controlling Shareholder and Its Wholly-owned Subsidiary and Related Party Transactions
June 5, 2026
Announcement on Progress in Repurchasing Shares through Call Auction
June 2, 2026
Announcement on Shareholding Reduction Plan for Senior Management Members
May 28, 2026
Announcement on Implementation of Dividend Distribution for 2025
May 27, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 12, 2026
Announcement on Convening Performance Briefing for 2025 and Q1 2026
April 28, 2026
Announcement on 2025 Annual Profit Distribution Plan
April 20, 2026
Announcement on Obtaining the Approval for Supplementary Application for Drugs for the Core Product Freeze-dried Rabies Vaccine (Vero Cells)
April 17, 2026
Announcement on the Resignation of Independent Directors upon Expiration of Their Term
March 17, 2026
Announcement on Wholly-owned Subsidiary's Passing GMP Compliance Inspection for Drugs
March 9, 2026
Announcement on Preliminary Earnings Estimate for 2025
February 27, 2026
Announcement on Obtaining the Drug Registration Certificate for Freeze-dried Rabies Vaccine (Human Diploid Cell)
February 24, 2026
Announcement on Obtaining Notice of Approval for Drug Clinical Trials for Influenza Virus Split Vaccine (High Dose)
February 12, 2026
Announcement on Outward Investing in Establishing a Wholly-owned Subsidiary
January 26, 2026
Announcement on Subsidiary Opening a Special Account for Raised Funds and Signing a Tripartite Supervision Agreement on Special Account Deposit of Raised Funds
January 5, 2026
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
December 31, 2025